KRAS and non-small cell lung carcinoma: In 86 ICI-treated NSCLC patients with evaluable baseline ctDNA, the presence of PTEN or STK11 mutation was correlated with early disease progression (HR = 8.9, p = 0.09 for PTEN; HR = 4.7, p = 0.003 for STK11) while transversion mutations (conversion between purine and pyrimidine) in KRAS and TP53 predicted better clinical outcomes (HR = 0.36, p = 0.011 for TP53; HR = 0.46, p = 0.11 for KRAS) [86].